JP2016094450A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016094450A5 JP2016094450A5 JP2015246156A JP2015246156A JP2016094450A5 JP 2016094450 A5 JP2016094450 A5 JP 2016094450A5 JP 2015246156 A JP2015246156 A JP 2015246156A JP 2015246156 A JP2015246156 A JP 2015246156A JP 2016094450 A5 JP2016094450 A5 JP 2016094450A5
- Authority
- JP
- Japan
- Prior art keywords
- ppe
- drug
- subject
- inhibitor
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940079593 drug Drugs 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 229960003310 sildenafil Drugs 0.000 claims description 4
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 3
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 3
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 3
- 229960004117 capecitabine Drugs 0.000 claims description 3
- 229960001796 sunitinib Drugs 0.000 claims description 3
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 3
- 230000004064 dysfunction Effects 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims 5
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims 5
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 15
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 15
- 238000000034 method Methods 0.000 description 13
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 11
- 206010070863 Toxicity to various agents Diseases 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 101100002068 Bacillus subtilis (strain 168) araR gene Proteins 0.000 description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 2
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 101150044616 araC gene Proteins 0.000 description 2
- 229960000307 avanafil Drugs 0.000 description 2
- WEAJZXNPAWBCOA-INIZCTEOSA-N avanafil Chemical compound C1=C(Cl)C(OC)=CC=C1CNC1=NC(N2[C@@H](CCC2)CO)=NC=C1C(=O)NCC1=NC=CC=N1 WEAJZXNPAWBCOA-INIZCTEOSA-N 0.000 description 2
- -1 bevacizumab Chemical compound 0.000 description 2
- 229960000908 idarubicin Drugs 0.000 description 2
- 229960002639 sildenafil citrate Drugs 0.000 description 2
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 2
- 229960000835 tadalafil Drugs 0.000 description 2
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 2
- 229960000438 udenafil Drugs 0.000 description 2
- IYFNEFQTYQPVOC-UHFFFAOYSA-N udenafil Chemical compound C1=C(C=2NC=3C(CCC)=NN(C)C=3C(=O)N=2)C(OCCC)=CC=C1S(=O)(=O)NCCC1CCCN1C IYFNEFQTYQPVOC-UHFFFAOYSA-N 0.000 description 2
- 229960002381 vardenafil Drugs 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229950002216 linifanib Drugs 0.000 description 1
- MPVGZUGXCQEXTM-UHFFFAOYSA-N linifanib Chemical compound CC1=CC=C(F)C(NC(=O)NC=2C=CC(=CC=2)C=2C=3C(N)=NNC=3C=CC=2)=C1 MPVGZUGXCQEXTM-UHFFFAOYSA-N 0.000 description 1
- 229950002245 mirodenafil Drugs 0.000 description 1
- MIJFNYMSCFYZNY-UHFFFAOYSA-N mirodenafil Chemical compound C1=C(C=2NC=3C(CCC)=CN(CC)C=3C(=O)N=2)C(OCCC)=CC=C1S(=O)(=O)N1CCN(CCO)CC1 MIJFNYMSCFYZNY-UHFFFAOYSA-N 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 239000004066 vascular targeting agent Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27909109P | 2009-10-16 | 2009-10-16 | |
| US61/279,091 | 2009-10-16 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012534390A Division JP2013508295A (ja) | 2009-10-16 | 2010-10-15 | 薬物誘発性手足症候群を治療するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016094450A JP2016094450A (ja) | 2016-05-26 |
| JP2016094450A5 true JP2016094450A5 (enExample) | 2016-10-13 |
| JP6063550B2 JP6063550B2 (ja) | 2017-01-18 |
Family
ID=43876575
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012534390A Pending JP2013508295A (ja) | 2009-10-16 | 2010-10-15 | 薬物誘発性手足症候群を治療するための組成物および方法 |
| JP2015246156A Active JP6063550B2 (ja) | 2009-10-16 | 2015-12-17 | 薬物誘発性手足症候群を治療するための組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012534390A Pending JP2013508295A (ja) | 2009-10-16 | 2010-10-15 | 薬物誘発性手足症候群を治療するための組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9220713B2 (enExample) |
| EP (1) | EP2488642B1 (enExample) |
| JP (2) | JP2013508295A (enExample) |
| CN (1) | CN102648279B (enExample) |
| AU (1) | AU2010306671B2 (enExample) |
| WO (1) | WO2011047256A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013508295A (ja) * | 2009-10-16 | 2013-03-07 | デューク・ユニヴァーシティ | 薬物誘発性手足症候群を治療するための組成物および方法 |
| US20140127295A1 (en) * | 2011-03-14 | 2014-05-08 | Cellworks Group, Inc | Compositions, process of preparation of said compositions and method of treating inflammatory diseases |
| WO2014201127A2 (en) * | 2013-06-11 | 2014-12-18 | Kala Pharmaceuticals, Inc. | Urea derivatives and uses thereof |
| WO2016144230A1 (en) * | 2015-03-06 | 2016-09-15 | Telefonaktiebolaget Lm Ericsson (Publ) | Method, network device, computer program and computer program product for mobile service chaining |
| EP3444337B1 (en) * | 2017-08-18 | 2024-12-18 | The Procter & Gamble Company | Method of cleaning |
| CN111601617A (zh) | 2017-12-13 | 2020-08-28 | 上海岸阔医药科技有限公司 | 一种用于预防或治疗与egfr 被抑制相关疾病的方法 |
| JP7520366B2 (ja) | 2018-04-16 | 2024-07-23 | オンクオリティー ファーマシューティカルズ チャイナ リミテッド | 腫瘍療法の副作用の予防または治療方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2002A (en) * | 1841-03-12 | Tor and planter for plowing | ||
| US9004A (en) * | 1852-06-08 | Improvement in seed-planters | ||
| US9019A (en) * | 1852-06-15 | Charles fleischbl | ||
| US20020028237A1 (en) * | 2000-04-20 | 2002-03-07 | Colbern Gail T. | Method for reducing toxicity of a cytotoxic agent |
| US6683080B2 (en) * | 2001-02-02 | 2004-01-27 | Pfizer Inc. | Treatment of diabetes mellitus |
| US20090048179A1 (en) * | 2005-02-22 | 2009-02-19 | Cedars-Sinai Medical Center | Use of 5-phosphodiesterase inhibitors to enhance the permeability of the blood-brain barrier of abnormal brain tissue and the blood-tumor barrier |
| US20080188480A1 (en) * | 2005-02-22 | 2008-08-07 | Cedars-Sinai Medical Center | Use of Sildenafil, Vardenafil and Other 5-Phosphodiesterase Inhibitors to Enhance Permeability of the Abnormal Blood-Brain Barrier |
| TWI435729B (zh) | 2005-11-09 | 2014-05-01 | Combinatorx Inc | 治療病症之方法，組合物及套組 |
| WO2007087575A2 (en) | 2006-01-24 | 2007-08-02 | University Of Chicago | Compositions and methods for treating pulmonary hypertension |
| DE602007004849D1 (de) | 2006-06-01 | 2010-04-01 | Nobera Pharma Sl | Verwendung von allopurinol zur behandlung von palmarer/plantarer erythrodysästhesie |
| EP2246057A1 (en) | 2009-04-29 | 2010-11-03 | Nobera Pharma, S.L. | Use of allopurinol for the treatment of hand foot skin reaction |
| JP2013508295A (ja) * | 2009-10-16 | 2013-03-07 | デューク・ユニヴァーシティ | 薬物誘発性手足症候群を治療するための組成物および方法 |
-
2010
- 2010-10-15 JP JP2012534390A patent/JP2013508295A/ja active Pending
- 2010-10-15 WO PCT/US2010/052836 patent/WO2011047256A1/en not_active Ceased
- 2010-10-15 CN CN201080057133.2A patent/CN102648279B/zh active Active
- 2010-10-15 AU AU2010306671A patent/AU2010306671B2/en active Active
- 2010-10-15 US US13/502,209 patent/US9220713B2/en active Active
- 2010-10-15 EP EP10824160.5A patent/EP2488642B1/en active Active
-
2015
- 2015-11-19 US US14/946,340 patent/US9629845B2/en active Active
- 2015-12-17 JP JP2015246156A patent/JP6063550B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016094450A5 (enExample) | ||
| JP2013508295A5 (enExample) | ||
| JP2017031160A5 (enExample) | ||
| JP2012509889A5 (enExample) | ||
| JP2010248252A5 (enExample) | ||
| JP2013173775A5 (enExample) | ||
| JP2010270124A5 (enExample) | ||
| JP2013507415A5 (enExample) | ||
| JP2017505321A5 (enExample) | ||
| NZ714963A (en) | Compositions and methods for treating anemia | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| IL319574A (en) | Non-selective metabotropic glutamate receptor agonists for the treatment of attention deficit hyperactivity disorder and 22Q syndrome | |
| JP2020521797A5 (enExample) | ||
| JP6063550B2 (ja) | 薬物誘発性手足症候群を治療するための組成物および方法 | |
| JP2017537936A5 (enExample) | ||
| JP2018519300A5 (enExample) | ||
| JP2014530181A5 (enExample) | ||
| RU2018146504A (ru) | Лечение внутрипеченочных холестатических заболеваний | |
| JP2019518030A5 (enExample) | ||
| JP2018505218A5 (enExample) | ||
| JP2014534229A5 (enExample) | ||
| JP2014513121A5 (enExample) | ||
| BR112020003585A2 (pt) | composição para uso no tratamento, prevenção ou retardamento da progressão de tumores sólidos que incluem câncer em um ser humano | |
| WO2017013490A3 (en) | Therapeutic combinations of orally administered paclitaxel and a p-gp inhibitor for the treatment of cancer | |
| JP2016503035A5 (enExample) |